Vaccine Adjuvants Market by Product Type (Pathogen, Adjuvant Emulsion, Particulate, Combination, Others), by Route of Administration(Oral, Intradermal, Intranasal, Intramuscular, Subcutaneous), by Disease Type(Infectious Disease, Cancer), by Application(Research, Commercial) by Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast 2023-2032

Report Overview

Vaccine Adjuvants Market size is expected to be worth around USD 2.5 Bn by 2032 from USD 0.9 Bn in 2022, growing at a CAGR of 10.6% during the forecast period from 2023 to 2032.

Request Covid - 19 Impact

Vaccine adjuvants help the body to build a strong immune response to protect the person from the disease. Adjuvants are added to vaccines to work better by improving the response of the body to vaccination and reducing the number of vaccine doses given to patients.

Major factors driving the growth of the global vaccine adjuvants market are increasing technological advancements focusing on improved and long-lasting vaccines for existing and emerging chronic diseases and growing government expenditure on research and development of adjuvant vaccines. Additionally, R&D enables evaluating adjuvant safety and efficacy for improving and standardizing animal models and correlating different immune responses with individual characteristics such as age, gender, ethnicity, genetics, underlying chronic illness, etc.

Increasing demand for vaccine adjuvants for preventing various high predominant chronic diseases such as arthritis, cancer, diabetes, epilepsy, obesity, allergy, etc. is projected to drive the growth of the target market. Vaccines are among some of the most effective medical inventions against various infectious diseases, and sometimes require a molecule in conjugation that enhances its immune response.

However, less safety pertaining to vaccine adjuvants is expected to hamper the growth of the global target market to a certain extent. Adjuvants act as immune-stimulants and may induce unwanted immune processes that could trigger the arrival of the immune-mediated disease in vulnerable individuals.

The development of new vaccine adjuvants required for pandemic diseases like influenza is a factor expected to create a lucrative opportunity for driving the growth of the target market in the next coming years.

Driving factors

An increasing number of cases of infectious diseases all around the world

There are a number of reasons that will likely result in a favorable impact for the vaccine adjuvants market. To begin, one of the key factors that is fueling the demand for effective vaccine solutions is the increased occurrence of infectious diseases all over the world. Adjuvants can improve the immune system's reaction to vaccinations, which in turn makes vaccines more efficient at warding off disease. In addition, scientific advances in the field of adjuvant development have boosted the efficacy and safety of vaccinations, which has resulted in an increase in the use of vaccines. The expansion of investments made in activities related to research & development is another factor that is driving the growth of this market.

An ever-increasing demand for safe and efficient vaccine solutions

An additional element that is driving demand is the expanding population of elderly people all over the world. This is leading to an increase in the need for vaccinations that are able to effectively protect elderly people from a variety of diseases. The expansion of the vaccine adjuvants market is also being driven by the growing knowledge about immunization programs and the significance of vaccination. Personalized medicine is yet another developing trend that is driving up demand for adjuvants because these treatments can be adapted to the specific requirements of each patient.

initiatives and regulations that are beneficially issued by the government

In addition, advantageous government actions and regulations are fostering an environment that is supportive of the expansion of the vaccine adjuvants market. For example, a number of nations have initiated vaccination programs with the intention of halting the spread of illnesses, which is what is driving the demand for adjuvants.

Recent scientific breakthroughs in the area of adjuvant research and development

Finally, shifts in consumer behavior, such as the growing demand for natural and organic vaccinations or the development in vaccine hesitancy, could also have an effect on the vaccine adjuvants market. Despite this, the overall growth prospects for the market continue to seem promising as a result of the rising demand for vaccines that are proven to be efficacious as well as the continued progress made in the research and development of adjuvants.

Restraining Factors

Stringent regulatory guidelines for adjuvant approval

Vaccine adjuvants have emerged as a crucial component in vaccine development and production, enhancing the efficacy of vaccines and providing long-term protection from infectious diseases. However, the vaccine adjuvants market faces several restraining factors that hinder its growth, such as stringent regulatory guidelines for adjuvant approval, high costs associated with adjuvant development and production, a limited understanding of immune system mechanisms, side-effects associated with adjuvant usage, and a growing preference for alternative medicine and therapies.

Regulatory guidelines for adjuvant approval continue to be the leading market restraint for vaccine adjuvants. Before obtaining regulatory approval, adjuvants must adhere to stringent guidelines established by regulatory bodies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These guidelines require extensive preclinical and clinical data, including testing for toxicity, immunogenicity, and efficacy. The time-consuming and expensive regulatory approval process exerts significant pressure on small businesses and start-ups with limited resources, effectively retarding the vaccine adjuvants market's expansion.

Costly adjuvant development and manufacturing

The costly development and production costs of adjuvants are also a significant limiting factor. Development and production of adjuvants demand extensive research, development, and testing, which can be costly. In addition, the production of adjuvants requires specialized apparatus and facilities, which can increase production costs. Additionally, the high cost of adjuvant development and production impacts the final price of vaccines, rendering them unaffordable for patients in low-income regions.

insufficient knowledge of immune system mechanisms

The limited understanding of immune system mechanisms has also been identified as a factor inhibiting market growth for vaccine adjuvants. Although vaccine adjuvants are used to enhance the immune response to vaccines, the underlying mechanisms remain poorly understood. Particularly obscure are the long-term effects of adjuvants on the immune system, posing a formidable challenge for researchers and pharmaceutical companies.

by Product Type Analysis

On the basis of product type segmentation, the particulate segment is expected to contribute a major revenue share and is projected to maintain its dominance over the forecast period. This dominance is attributed to the increasing adoption of pathogen adjuvants for the treatment of various diseases such as hepatitis B, and human papillomavirus coupled with the increasing prevalence of these diseases across the globe.

by Route of Administration Analysis

On the basis of route of administration segmentation, the intramuscular segment is expected to contribute a major revenue share of the market and is expected to maintain its dominance over the forecast period. The intramuscular segment is projected to register a significant CAGR of over 10.2%, over the forecast period, owing to increasing demand for intramuscular vaccine adjuvants to treat various diseases such as influenza, human papillomavirus (HPV), coupled with the increasing prevalence of these diseases.

By Disease Type Analysis

On the basis of disease type segmentation, the infectious disease segment is expected to contribute a major revenue share of the market and is expected to maintain its dominance over the forecast period. The infectious disease segment is projected to register a significant CAGR of over 10.1%, over the forecast period. The growing prevalence of infectious diseases such as malaria, influenza, hepatitis A, B, & C, and others in developed and developing countries is expected to support the revenue growth of the segment.

By Application Analysis

On the basis of application segmentation, the research segment is expected to contribute a major revenue share of the market and is expected to maintain its dominance over the forecast period. The research segment is projected to register a significant CAGR of over 10%, over the forecast period, owing to various research institutes and government organizations for R&D of adjuvants and vaccines.

Key Market Segments

By Product Type:

• Pathogen
• Adjuvant Emulsion
• Particulate
• Combination
• Others

By Route of Administration:

• Oral
• Intradermal
• Intranasal
• Intramuscular
• Subcutaneous

By Disease Type:

• Infectious Disease
• Cancer

By Application:

• Research
• Commercial

Growth Opportunity

Increasing Interest in Personalized Medicine

Personalized medicine is a rapidly expanding field that seeks to improve patient outcomes by individualizing treatments. Vaccines are not an exception, and personalized vaccines tailored to the specific requirements of an individual represent a promising area of research. This is because vaccines do not function the same way for everyone, and better outcomes can be achieved by tailoring vaccines to an individual's genetic profile or immune response. This is fueling demand for vaccine adjuvants that can boost the efficacy of personalized vaccines.

Increasing Incidence of Infectious Diseases

Infectious diseases continue to pose a significant threat to global public health. In recent years, the incidence of several infectious diseases, including influenza, measles, and pertussis, has increased. This is increasing the demand for novel and improved vaccines, and adjuvants are crucial to the development of effective vaccines against these diseases.

Advancements in Adjuvant Research and Technology

In recent years, there have been significant advances in adjuvant research and technology development. The use of nanoparticles as adjuvants, which can substantially boost the immune response to vaccines, is one example. The use of Toll-like receptor agonists and novel formulations of adjuvants, such as emulsions and liposomes, are additional developments. These developments are driving demand for vaccine adjuvants that can leverage these novel technologies.

Latest Trends

Increasing Focus on Combination Vaccines

Combination vaccines, which contain multiple active ingredients, are gaining popularity due to their effectiveness and convenience. With the development of more adjuvants for therapeutic vaccines, it is now feasible to combine multiple antigens in a single vaccine. This trend is propelling the growth of the vaccine adjuvants market, as more companies investigate the use of adjuvants to enhance the efficacy of combination vaccines.

Increase in Public-Private Partnerships for the Development of Vaccines

The prevalence of public-private partnerships (PPPs) in vaccine development is increasing as governments and NGOs seek to leverage private sector expertise and funding to accelerate vaccine development and distribution. Partnerships of this nature frequently concentrate on the development of vaccines for diseases that primarily affect developing countries, where there are few commercial incentives for private companies to invest in vaccine development. The increase in PPPs for vaccine development is driving the expansion of the vaccine adjuvants market, as adjuvants are frequently included in vaccines developed through these partnerships.

Innovative Vaccine Adjuvant Technology Adoption

In recent years, novel vaccine adjuvant technologies that enable for more targeted and effective stimulation of the immune system have been developed. There are nanoparticles, liposomes, and immunostimulatory complexes among these technologies. The adoption of these technologies is driving the growth of the vaccine adjuvants market, as they are more effective at boosting the immune response and reducing the doses of vaccine adjuvants required.

Regional Analysis

The market in North America accounted for a major revenue share in the global vaccine adjuvants market in 2022 and is projected to maintain its dominance over the forecast period. The North American vaccine adjuvants market is expected to register a significant CAGR during the forecast period. Demand for vaccine adjuvants has been increasing significantly due to the presence of advanced medical facilities and developed healthcare infrastructure, coupled with the high adoption of technologically advanced healthcare products and devices in countries in the region. In addition, increasing government initiatives for spreading awareness about various infectious diseases and cancers, coupled with favorable reimbursement policies, is another factor expected to drive revenue growth of the market in the region.

The Asia Pacific market is projected to register the highest CAGR of over 10.6% in the global vaccine adjuvants market during the forecast period. This can be attributed to the increasing incidence of various infectious diseases, the presence of a large patient pool, and increasing government initiatives for spreading awareness about the treatment of various diseases, especially in emerging economies such as China and India. Furthermore, the increasing geriatric population and increasing incidence of obesity and diabetes, which could lead to severe health problems including cancer, are among other factors expected to propel the need for developed and well-equipped medical care facilities, which in turn is projected to fuel the growth of the Asia Pacific vaccine adjuvants market over the forecast period

The market in Middle East & Africa accounted for considerable revenue share in the global vaccine adjuvants market and is projected to register a CAGR of over 9% over the forecast period.

Key Regions and Countries

North America

• US
• Canada
• Mexico

Western Europe

• Germany
• France
• The UK
• Spain
• Italy
• Portugal
• Ireland
• Austria
• Switzerland
• Benelux
• Nordic
• Rest of Western Europe

Eastern Europe

• Russia
• Poland
• The Czech Republic
• Greece
• Rest of Eastern Europe

APAC

• China
• Japan
• South Korea
• India
• Australia & New Zealand
• Indonesia
• Malaysia
• Philippines
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Colombia
• Chile
• Argentina
• Costa Rica
• Rest of Latin America

Middle East & Africa

• Algeria
• Egypt
• Israel
• Kuwait
• Nigeria
• Saudi Arabia
• South Africa
• Turkey
• United Arab Emirates
• Rest of MEA

Market Share & Key Players Analysis

With leading companies investing more in R&D, the vaccine adjuvants market has grown rapidly. This has led to the development of new goods and technology that strengthen the immune system to promote vaccine efficacy.Brenntag Biosector, Invivogen, OZ Biosciences, SEPPIC, SPI Pharma, Sigma-Aldrich, and Agenus Inc. are vaccine adjuvants market leaders. These companies are releasing new goods, increasing manufacturing capacity, and forming strategic partnerships to improve their market positions.

In October 2020, Brenntag Biosector added distribution of GreenLight Biosciences' mRNA vaccine technology to its deal. In May 2018, Agenus Inc. and Gilead Sciences agreed to develop and market immuno-oncology treatments using Agenus' antibody platform technology.Due to rising demand for effective and safe vaccinations, rising infectious illness rates, and technological improvements, the vaccine adjuvants market is predicted to rise significantly. To stay ahead in a competitive market, important firms must focus on innovation, strategic relationships, and collaborations.

Top Key Players in Vaccine Adjuvants Market

• Brenntag Biosector A/S
• CSL Limited
• Air Liquide S.A.
• Agenus Inc.
• Novavax, Inc.
• Associated British Foods plc (SPI Pharma, Inc.)
• InvivoGen Inc.
• Avanti Polar Lipids, Inc.
• MVP Laboratories Inc.
• OZ Biosciences

Recent Development

In 2021, Recent advancements have sent the vaccine adjuvants market into a frenzy. GlaxoSmithKline (GSK) and CureVac announced a collaboration to develop mRNA-based COVID-19 vaccines incorporating GSK's adjuvant technology in May 2021. This was followed by the June 2021 announcement by Vaxine Pty Ltd of positive results from a Phase 1 clinical trial of its COVID-19 vaccine candidate using the company's Advax adjuvant technology.

Later in August 2021, Seqirus introduced FLUAD QUADRIVALENT, a seasonal influenza vaccine containing MF59 adjuvant technology. This was followed by the September 2021 announcement by Novavax that its COVID-19 vaccine candidate using the company's Matrix-M adjuvant technology demonstrated a 90.4% efficacy rate in a Phase 3 clinical trial.

Nanomerics announced in October 2021 that it had received funding from the United Kingdom government to develop a new adjuvant platform for vaccines based on its proprietary vesicle technology. This announcement kept the momentum going. In November 2021, the World Health Organization (WHO) also approved the use of the new adjuvant AS03 in COVID-19 vaccines. AS03 is presently utilized in the Shingrix vaccine by GSK.

in 2022 , Altimmune began a Phase 1 clinical trial of its intranasal COVID-19 vaccine candidate using the company's AdCOVID adjuvant technology in February 2022. The Bill & Melinda Gates Foundation recently, in March 2022, announced a $200 million investment in adjuvant technology research and development, with an emphasis on vaccines for infectious diseases.

Report Scope: